Neuroprotection for Ischemic Stroke: Moving Past Shortcomings and Identifying Promising Directions

The translation of neuroprotective agents for ischemic stroke from bench-to-bedside has largely failed to produce improved treatments since the development of tissue plasminogen activator (tPA). One possible reason for lack of translation is the failure to acknowledge the greatest risk factor for st...

Full description

Bibliographic Details
Main Authors: Jason D. Huber, Charles L. Rosen, Aric F. Logsdon, Alisa S. Elliott, Noelle Lucke-Wold, Ryan C. Turner, Brandon Lucke-Wold
Format: Article
Language:English
Published: MDPI AG 2013-01-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:http://www.mdpi.com/1422-0067/14/1/1890
id doaj-47ef36b024204f699cdc99c61a3ace09
record_format Article
spelling doaj-47ef36b024204f699cdc99c61a3ace092020-11-24T21:36:14ZengMDPI AGInternational Journal of Molecular Sciences1422-00672013-01-011411890191710.3390/ijms14011890Neuroprotection for Ischemic Stroke: Moving Past Shortcomings and Identifying Promising DirectionsJason D. HuberCharles L. RosenAric F. LogsdonAlisa S. ElliottNoelle Lucke-WoldRyan C. TurnerBrandon Lucke-WoldThe translation of neuroprotective agents for ischemic stroke from bench-to-bedside has largely failed to produce improved treatments since the development of tissue plasminogen activator (tPA). One possible reason for lack of translation is the failure to acknowledge the greatest risk factor for stroke, age, and other common comorbidities such as hypertension, obesity, and diabetes that are associated with stroke. In this review, we highlight both mechanisms of studying these factors and results of those that have been addressed. We also discuss the potential role of other lifestyle factors associated with an increased stroke risk such as sleep fragmentation and/or deprivation. Furthermore, many proposed therapeutic agents have targeted molecular mechanisms occurring soon after the onset of ischemia despite data indicating delayed patient presentation following ischemic stroke. Modulating inflammation has been identified as a promising therapeutic avenue consistent with preliminary success of ongoing clinical trials for anti-inflammatory compounds such as minocycline. We review the role of inflammation in stroke and in particular, the role of inflammatory cell recruitment and macrophage phenotype in the inflammatory process. Emerging evidence indicates an increasing role of neuro-immune crosstalk, which has led to increased interest in identification of peripheral biomarkers indicative of neural injury. It is our hope that identification and investigation of factors influencing stroke pathophysiology may lead to improved therapeutics.http://www.mdpi.com/1422-0067/14/1/1890ischemic strokecomorbidityagingmacrophage polarization
collection DOAJ
language English
format Article
sources DOAJ
author Jason D. Huber
Charles L. Rosen
Aric F. Logsdon
Alisa S. Elliott
Noelle Lucke-Wold
Ryan C. Turner
Brandon Lucke-Wold
spellingShingle Jason D. Huber
Charles L. Rosen
Aric F. Logsdon
Alisa S. Elliott
Noelle Lucke-Wold
Ryan C. Turner
Brandon Lucke-Wold
Neuroprotection for Ischemic Stroke: Moving Past Shortcomings and Identifying Promising Directions
International Journal of Molecular Sciences
ischemic stroke
comorbidity
aging
macrophage polarization
author_facet Jason D. Huber
Charles L. Rosen
Aric F. Logsdon
Alisa S. Elliott
Noelle Lucke-Wold
Ryan C. Turner
Brandon Lucke-Wold
author_sort Jason D. Huber
title Neuroprotection for Ischemic Stroke: Moving Past Shortcomings and Identifying Promising Directions
title_short Neuroprotection for Ischemic Stroke: Moving Past Shortcomings and Identifying Promising Directions
title_full Neuroprotection for Ischemic Stroke: Moving Past Shortcomings and Identifying Promising Directions
title_fullStr Neuroprotection for Ischemic Stroke: Moving Past Shortcomings and Identifying Promising Directions
title_full_unstemmed Neuroprotection for Ischemic Stroke: Moving Past Shortcomings and Identifying Promising Directions
title_sort neuroprotection for ischemic stroke: moving past shortcomings and identifying promising directions
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1422-0067
publishDate 2013-01-01
description The translation of neuroprotective agents for ischemic stroke from bench-to-bedside has largely failed to produce improved treatments since the development of tissue plasminogen activator (tPA). One possible reason for lack of translation is the failure to acknowledge the greatest risk factor for stroke, age, and other common comorbidities such as hypertension, obesity, and diabetes that are associated with stroke. In this review, we highlight both mechanisms of studying these factors and results of those that have been addressed. We also discuss the potential role of other lifestyle factors associated with an increased stroke risk such as sleep fragmentation and/or deprivation. Furthermore, many proposed therapeutic agents have targeted molecular mechanisms occurring soon after the onset of ischemia despite data indicating delayed patient presentation following ischemic stroke. Modulating inflammation has been identified as a promising therapeutic avenue consistent with preliminary success of ongoing clinical trials for anti-inflammatory compounds such as minocycline. We review the role of inflammation in stroke and in particular, the role of inflammatory cell recruitment and macrophage phenotype in the inflammatory process. Emerging evidence indicates an increasing role of neuro-immune crosstalk, which has led to increased interest in identification of peripheral biomarkers indicative of neural injury. It is our hope that identification and investigation of factors influencing stroke pathophysiology may lead to improved therapeutics.
topic ischemic stroke
comorbidity
aging
macrophage polarization
url http://www.mdpi.com/1422-0067/14/1/1890
work_keys_str_mv AT jasondhuber neuroprotectionforischemicstrokemovingpastshortcomingsandidentifyingpromisingdirections
AT charleslrosen neuroprotectionforischemicstrokemovingpastshortcomingsandidentifyingpromisingdirections
AT aricflogsdon neuroprotectionforischemicstrokemovingpastshortcomingsandidentifyingpromisingdirections
AT alisaselliott neuroprotectionforischemicstrokemovingpastshortcomingsandidentifyingpromisingdirections
AT noelleluckewold neuroprotectionforischemicstrokemovingpastshortcomingsandidentifyingpromisingdirections
AT ryancturner neuroprotectionforischemicstrokemovingpastshortcomingsandidentifyingpromisingdirections
AT brandonluckewold neuroprotectionforischemicstrokemovingpastshortcomingsandidentifyingpromisingdirections
_version_ 1725942290883543040